HIV Meds Update - RAPID: Immediate ART Initiation

Publish Date: 
Tuesday, September 27, 2016

This publication presents the results of San Francisco General Hospital's Ward 86 pilot study of immediate ART initiation. This RAPID program systematically offered ART to patients upon diagnosis of HIV; patients were referred from HIV testing sites in San Francisco. Of the 39 patients who participated in the pilot, 95% of them started ART within 24 hours.

HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052

Publish Date: 
Tuesday, September 27, 2016

The PARTNER Study, a multisite European study, evaluated rates of HIV transmissions within serodifferent heterosexual and MSM couples (n = 548 and n = 340, respectively, contributed eligible data). The HIV-positive partners were on ART with HIV RNA levels of <200 copies/mL, and the couples engaged in ongoing condomless sex (vaginal and/or anal) during a median of 1.3 years per couple (1,238 "couple years"). It was noted that 33% of HIV-negative MSM had outside partners, compared with 4% of HIV-negative heterosexual subjects).

HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA

Publish Date: 
Tuesday, September 27, 2016

We know that very early treatment in acute HIV infection decreases HIV RNA; this study shows it also greatly decreases proviral DNA (and reservoir size). Researchers investigated 2 small cohorts of patients in Thailand with acute (and very early) HIV infection, 1 untreated and 1 treated with ART very early; patients were followed for 144 weeks. They found that DNA integration occurs early and rapidly, and that with early and continued ART, total and integrated HIV DNA drops quickly and continues to decrease over time.

HIV and Heart Disease – NIH Explores the Connection

Publish Date: 
Wednesday, June 15, 2016

HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20-year-old on effective antiretroviral therapy (ART) can expect to live into their 70s, a lifespan only slightly lower than in people without HIV.[1] While this is great news, physicians are learning that chronic HIV infection can place their patients at a higher risk of developing certain health problems earlier in life. One example is heart disease.

Accessibility: The Bigger Picture

Publish Date: 
Thursday, June 2, 2016

selection from infographic. 74.8 million adults in the U.S. have at least one disibility or mobility limitation.I have been working on website accessibility for many years in my role as Production Manager at the UCSF Center for HIV Information. Despite that experience, I still encounter problems that confound me. I recently reached out to an accessibility expert for ideas on how to manage a particularly difficult compliance problem.

Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

Publish Date: 
Tuesday, April 12, 2016

Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted darunavir during pregnancy.

Switching from TDF/FTC to TAF/FTC

Publish Date: 
Friday, March 18, 2016

Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg with boosted PIs, 200/25 mg without boosters) or continued on TDF/FTC; the background third agents were not changed. At 48 weeks, 94.3% of TAF/FTC recipients and 93% of TDF/FTC recipients maintained HIV RNA suppression; the difference was not significant.

Pages

Subscribe to Sharespot RSS feed